News articles about AMAG Pharmaceuticals (NASDAQ:AMAG) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AMAG Pharmaceuticals earned a news impact score of 0.23 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 45.576622132864 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern’s analysis:
- Featured Volatile Stock – AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) – The Investor Guide (wallstreetnews24.com)
- AMAG Pharmaceuticals, Inc. (AMAG) – 52-Weeks Low Effect in Stock – The Stocks News (press release) (thestocksnews.com)
- AMAG Pharmaceuticals, Inc. (AMAG) – 52-Week New High Stock to Track – The Stocks News (press release) (thestocksnews.com)
- Digging Deep into the Quant Data For AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Firstgroup plc (LSE:FGP) – Clawson News (clawsonnews.com)
- AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance – GlobeNewswire (press release) (globenewswire.com)
AMAG has been the topic of several recent research reports. Cantor Fitzgerald restated a “hold” rating and set a $21.00 target price on shares of AMAG Pharmaceuticals in a report on Thursday, September 28th. Zacks Investment Research lowered shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Tuesday, October 17th. Morgan Stanley reduced their target price on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a report on Friday, November 3rd. Finally, B. Riley initiated coverage on shares of AMAG Pharmaceuticals in a report on Thursday, December 7th. They set a “neutral” rating and a $16.00 target price on the stock. Twelve analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. AMAG Pharmaceuticals currently has an average rating of “Hold” and an average target price of $21.27.
AMAG Pharmaceuticals (AMAG) traded down $0.40 during trading on Friday, reaching $14.35. 1,024,300 shares of the company traded hands, compared to its average volume of 882,150. AMAG Pharmaceuticals has a 12-month low of $11.93 and a 12-month high of $25.20. The stock has a market cap of $510.80, a P/E ratio of -2.36 and a beta of 0.79. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48.
ILLEGAL ACTIVITY NOTICE: “AMAG Pharmaceuticals (AMAG) Receives News Sentiment Score of 0.23” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/01/12/amag-pharmaceuticals-amag-receives-news-sentiment-score-of-0-23.html.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.